ADHD and Depression Low Motivation Shame and Overlap

Last Reviewed on July 3, 2026
Reviewd By Burton J. Tabaac, MD, FAHA"
July 3, 2026

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

ADHD and depression can overlap because both can affect focus, motivation, sleep, energy, memory, emotion and daily follow through. ADHD often begins with lifelong attention, time, planning and impulse control problems. Depression often brings persistent low mood, loss of interest, low energy, sleep or appetite changes and thoughts of hopelessness. You can have ADHD, depression or both, so a careful clinical assessment should look at symptom timing, daily impairment, safety and the pattern behind missed tasks.

You may struggle to tell the difference because the surface signs can look similar. You may avoid work, fall behind, lose interest, sleep poorly or feel unable to begin basic tasks. ADHD can create repeated problems that lead to shame, stress and burnout. Depression can reduce energy and make ADHD symptoms feel heavier.

The key question is what starts the cycle. ADHD may start the cycle with missed deadlines, poor time sense, forgetfulness or task paralysis. Depression may start the cycle with low mood, loss of pleasure, slowed thinking or hopelessness. When both are present, they can feed each other.

Care should be guided by a qualified clinician. ADHD treatment may include medication, therapy, skills training, school or work support and daily routines. Depression treatment may include therapy, medication discussions, safety planning, sleep care and social support. If suicidal thoughts or self harm urges appear, urgent help is needed.

Fast answer for ADHD and depression

ADHD and depression share signs such as poor focus, low motivation, fatigue, sleep problems, irritability and unfinished tasks. ADHD usually involves long term problems with attention, organization, time and follow through that began earlier in life. Depression usually involves a sustained change in mood, pleasure, energy, sleep, appetite, self view and hope.

You may have ADHD if you have always struggled with task starts, time blindness, lost items, missed details or impulsive actions, even during periods when your mood was stable. You may have depression if you have a marked period of low mood, loss of interest, low energy, guilt, hopeless thoughts, sleep changes or appetite changes that affects daily life.

You can also have both. ADHD can increase stress through repeated missed tasks and conflict. Depression can make ADHD management harder by reducing energy and hope. The combination can make daily responsibilities feel much harder to start and finish.

A clinician should ask about childhood patterns, current mood, sleep, appetite, energy, concentration, safety, substance use, trauma, medical conditions and medication history. Treatment planning should address both symptom patterns when both are active.

Shared signs and key differences

ADHD and depression can both affect concentration. With ADHD, focus may shift away from the task because attention regulation is weak. You may drift during reading, miss details, lose track of steps or forget what you were doing. With depression, focus may feel slowed, heavy or foggy because energy and mood are low.

Both can affect motivation. ADHD motivation may depend strongly on interest, urgency, novelty and reward. You may want to do a task but feel unable to start until pressure becomes intense. Depression can reduce interest across many areas, including activities that usually feel meaningful or pleasant.

Both can affect sleep. ADHD can delay bedtime through time drift, racing thoughts, screen use or difficulty stopping tasks. Depression can lead to insomnia, early morning waking or sleeping much more than usual. Sleep loss can worsen both conditions.

Both can create irritability. ADHD irritability may appear during transitions, unclear tasks, interruptions or emotional overload. Depression related irritability may come with low mood, fatigue, hopelessness or feeling detached from daily life.

The difference often appears in the history. ADHD symptoms usually trace back to childhood, even if no one named them. Depression may begin later or appear in episodes. Some people have chronic depressive symptoms, so the clinician should ask carefully about both lifelong patterns and recent changes.

Low motivation and task avoidance

Low motivation is one of the hardest signs to interpret. You may think you are lazy, but both ADHD and depression can interfere with action. The clinical question is why action feels blocked.

With ADHD, task avoidance often happens when the task is boring, unclear, long, repetitive or far from reward. You may avoid paperwork, cleaning, studying, bills or messages. You may feel a burst of energy only when a deadline gets close. Once urgency appears, you may complete the task quickly, even if the process was stressful.

With depression, low motivation may feel broader. You may lose interest in work, hobbies, social contact, food, sex, hygiene or activities that usually feel good. You may feel slowed down, empty, hopeless or unable to care about outcomes. Even urgent tasks may feel impossible.

When ADHD and depression occur together, task avoidance can deepen. You may delay because ADHD makes the task hard to start. Then shame grows. Depression lowers energy and hope. The task begins to feel impossible. This cycle can lead to missed work, missed school, unpaid bills or withdrawal from people.

How to track the pattern

Write down the task, what happened before you avoided it and what you felt. If the main feeling was boredom, confusion or poor time sense, ADHD may be a driver. If the main feeling was hopelessness, numbness or loss of interest in most things, depression may be a driver.

Also track what helps. ADHD driven avoidance may improve with a timer, body doubling, a smaller first step or a clear deadline. Depression driven avoidance may need mood treatment, safety support, therapy and smaller demands while energy is low.

Why advice to try harder fails

Simple pressure often fails because neither ADHD nor depression is solved by force alone. ADHD needs external systems that support time, memory and task starts. Depression needs care for mood, energy, sleep, safety and loss of interest.

A better first step is to make the task smaller and get clinical support when symptoms interfere with daily life.

Shame after repeated problems

Shame is common when ADHD has gone unrecognized for years. You may have heard that you are careless, lazy, unreliable, messy or too sensitive. Over time, these labels can become part of how you speak to yourself.

Repeated problems can create a painful cycle. You miss a task, feel ashamed, avoid looking at it, fall further behind and then feel worse. The next task starts with more emotional weight because it reminds you of past failure.

Depression can intensify shame. You may begin to think that things cannot improve or that you are a burden. These thoughts should be taken seriously, especially when they come with withdrawal, hopelessness or thoughts of death.

Therapy can help you separate responsibility from self attack. You can name what happened, repair when needed and build a system for next time. You do not need to use shame as the tool for change.

ADHD burnout

ADHD burnout is a common phrase people use for exhaustion after long periods of overcompensation. You may have spent years masking symptoms, working late, rushing deadlines, apologizing and trying to keep up. Eventually, your energy may drop and tasks that were once barely manageable may feel impossible.

Burnout is not a formal ADHD diagnosis by itself. It can overlap with depression, anxiety, sleep loss and stress. If you feel persistently low, hopeless or unable to function, seek clinical assessment rather than assuming it is only burnout.

Repair without self punishment

If ADHD or depression has affected others, repair can be direct. Name the missed action, acknowledge the impact and add a practical next step. This may mean a shared task board, a reminder, a smaller work plan or a clinician appointment.

Repeated apology without a system can frustrate everyone. A repair plan gives the next attempt more support.

Sleep, appetite and mood clues

Sleep, appetite and mood changes can help a clinician sort the pattern. They do not give a diagnosis by themselves, but they provide useful clues.

ADHD related sleep problems often involve delayed bedtime, inconsistent routines, trouble stopping activities, restless thoughts or poor time sense at night. You may stay up because you lost track of time or because the quiet night hours feel easier for work.

Depression related sleep problems may include insomnia, waking too early, sleeping much more than usual or feeling exhausted despite sleep. Sleep may feel unrefreshing. You may struggle to get out of bed because the day feels heavy or pointless.

Appetite changes can also matter. Depression may reduce appetite or lead to increased eating. ADHD medication can affect appetite for some people. Stress and poor routines can also affect meals. A clinician should review appetite, weight change, medication timing and health history.

Mood clues are central. Depression often includes persistent sadness, emptiness, loss of pleasure, guilt, hopelessness or thoughts of death. ADHD can create frustration, shame and emotional reactions, but the mood may lift when the task is done, support appears or the environment changes. When low mood stays across settings and activities, depression needs direct attention.

Questions to ask yourself before assessment

You can prepare by writing notes on these areas.

  • Did attention and organization problems begin in childhood
  • Has your mood changed from your usual baseline
  • Have you lost interest in activities you normally enjoy
  • Are you sleeping much more or much less than usual
  • Has your appetite changed
  • Do you feel hopeless or like a burden
  • Do task problems improve with structure or remain heavy across situations
  • Are you using alcohol, cannabis, nicotine or other substances to cope
  • Have you had thoughts of death or self harm

Bring these notes to a clinician. They can help separate ADHD, depression and other causes.

Safety signs that need urgent help

Safety comes first when depression symptoms include thoughts of death, self harm urges or feeling unable to stay safe. Seek urgent help right away if you may harm yourself or someone else, feel out of control or cannot commit to staying safe.

Warning signs can include talking about wanting to die, looking for ways to harm yourself, feeling trapped, feeling like a burden, giving away possessions, saying goodbye, severe agitation, reckless behavior, extreme mood changes, heavy substance use or withdrawal from people.

If you are with someone at risk, stay with them if it is safe to do so, remove immediate dangers when possible and contact emergency services or a local crisis line. Do not leave a person alone if there is immediate risk.

Routine ADHD planning should wait until the safety risk is addressed. Depression with suicidal thoughts needs direct care. ADHD may still be part of the picture, but urgent safety support comes first.

Children and teens

For children and teens, take statements about death or self harm seriously. A young person may say something during conflict, but the statement still needs calm attention. Ask directly about safety and contact a clinician, crisis service or emergency service when risk is present.

Watch for withdrawal, sudden behavior changes, self harm marks, giving away items, online searches about death, severe irritability, substance use or major sleep changes. These signs need prompt adult action.

Adults

Adults may hide suicidal thoughts because they feel ashamed or fear burdening others. If you have these thoughts, tell someone you trust and seek urgent help. If someone tells you they are having these thoughts, listen directly and help them contact support.

Treatment planning for both conditions

When ADHD and depression are both present, treatment should address both. The order depends on severity, safety and daily impairment. If depression includes suicidal thoughts, severe hopelessness, psychosis, mania symptoms or inability to function, urgent mental health care is the first priority.

ADHD treatment may include medication, therapy, skills training, school support, work support, parent training and routines. Depression treatment may include psychotherapy, medication discussions, sleep care, behavioral activation, social support and safety planning. A clinician can help decide which steps should begin first.

Cognitive behavioral therapy can help with task avoidance, self criticism, mood patterns and daily planning. Behavioral activation may help depression by rebuilding small, planned activities when interest is low. ADHD skills work may help make those activities visible and easier to start.

Medication decisions should be made by a qualified prescriber. ADHD medications and depression medications can each have benefits and side effects. The prescriber should know your full health history, current medicines, sleep, appetite, substance use, mood symptoms, suicidal thoughts and family history of bipolar disorder when relevant.

Sleep care should be part of the plan. Poor sleep can worsen focus and mood. Your clinician may discuss bedtime routines, medication timing, insomnia treatment or screening for sleep disorders.

Substance use also needs honest review. Alcohol, cannabis, nicotine or other substances can affect mood, motivation, sleep and medication safety. Tell your clinician what you use and how often. This helps the plan fit your real life.

Psychedelic research has shown serious scientific interest in depression, including clinical trials of psilocybin assisted therapy in supervised settings. This research does not make psilocybin an approved ADHD treatment, and it should not replace evidence based care for ADHD, depression or safety risk.

Practical daily supports while care is being arranged

Use small steps while waiting for care. Choose one urgent task, one meal, one sleep cue and one person to contact if symptoms worsen. Put tasks in one place. Use short starts. Avoid making large life decisions during severe depressive periods when possible.

For ADHD and depression together, the first task may need to be very small. Open the message. Sit up. Drink water. Step outside for two minutes. Text a trusted person. These steps do not replace treatment, but they can reduce isolation and help you reach care.

Conclusion

As you review ADHD and depression, symptom overlap and current research limits, we at Rose Hill Life Sciences follow related questions through our work as a psychedelic research organization focused on the production and research of Psilocybe cubensis, with our role at the intersection of science and therapeutic integration reflected in our Massachusetts research work.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.